Background and objective: While multidisciplinary team (MDT) care in lung cancer is widely practiced, there are few guidelines for MDT on best data collection strategies. MDT meetings need ready access to information for the provision of optimal treatment recommendations (the primary purpose of the meeting), audit of team performance and benchmarking. This study aimed to develop a practical data set designed for these goals through a recognized consensus process with health professionals who participate in formal MDT settings. Methods: A modified Delphi process with three iterations (two surveys and one consensus conference) was carried out involving over 100 Australian lung cancer MDT health professionals. Results: In total, 122 lung cancer MDT health professionals responded to the Round 1 survey from over 350 invitees. Of the 122, 98 were available for invitation to Round 2. Of 98, 52 (53%) invitees responded to the Round 2 survey. After two rounds, 51 data elements across 8 domains (patient demographics, risk factors, biopsy data, staging, timeliness, treatment, follow-up and patient selection) achieved consensus, defined as 80% agreement. For Round 3, 33 MDT lead clinicians were invited to participate in a consensus conference. Of 33, 14 (42%) invitees distilled the 47 data elements into 23 elements across 8 domains to address the study objectives. Conclusion: A practical data set for lung cancer MDT to use for optimal treatment recommendations and to evaluate team performance was developed through recognized consensus methodology. Access to streamlined, relevant and feasible data collection strategies may
INTRODUCTION
Multidisciplinary care for lung cancer is accepted in many countries around the world [1] [2] [3] [4] [5] [6] [7] [8] [9] but collection of data by multidisciplinary team (MDT) is not yet routine or standardized. Data sources that provide information on the impact of MDT care include state cancer registries, 10 local cancer registries, 8 hospital-based registries 11 and (via linkage) national administrative data sets. 7 There are many different data sources and collection strategies for lung cancer, including the International Consortium for Health Outcomes (ICHOM)
SUMMARY AT A GLANCE
This study uses the Delphi process for consultation with lung cancer multidisciplinary team (MDT) health professionals to develop an optimized data set for MDT teams. This data set results from a practical approach to identify clinically useful data elements that facilitate standardization of MDT data collection, internal MDT review and future outcomes research.
database, 12 the National Lung Cancer Audit (NLCA) key data items, 13 the Dutch lung surgery audit 14, 15 and CancerLinQ 16 as well as registry data sets including the Victorian Lung Cancer Registry (VLCR) 17 and the Danish Lung Cancer Registry (DLCR). 18 These data sets are high quality and capture crucial information on case-mix variables and population-based outcomes. However, lung cancer MDT have different goals from registries and from population-based analyses. The purpose of the MDT is to provide optimal treatment recommendations for each patient and, if possible, to act as a focal point for evaluation of team-based quality of care. Therefore, a potential gap exists in the data strategy at this level. MDT need real-time information on, for example, risk factors, performance status and staging. Many published data sets are simply too big and too complex for routine clinical use. They may contain data elements that are critical for broader purposes but surplus to the scope of MDT practice. Several models for real-time clinical data collection exist including Queensland Oncology Online (QOOL) 19, 20 and CancerLINQ
16
; however, these models use sophisticated data integration strategies that may be beyond the current capability of many MDT. For MDT, smaller data sets with potential for benchmarking may prove more effective than larger, more complex data sets.
There are few guidelines for MDT data collection. A UK National Health Service (NHS) document 21 refers to 'locally agreed minimum data sets' but does not specify data elements for collection. Could data be collected from existing health platforms such as electronic health records and administrative data sources? This approach may face limitations such as delays in collection and variation in data quality and completeness 22 as well as difficulties with access to data and barriers such as patient consent, data ownership and governance issues, privacy and confidentiality. 22 Data sets that are designed to meet specific clinical and quality assurance needs of lung cancer MDT may better support day-to-day decision-making, evaluation of performance and comparison between services. For implementation and compliance, such data sets must be clinically relevant, comparatively modest in size, allow unproblematic data extraction and be straightforward to collect. To avoid duplication, data elements that are readily available from other sources may not require collection by MDT.
This study aimed to develop a consensus-based data set via a modified Delphi process, 23 with consultation from the Australian lung cancer MDT community, that would support MDT treatment recommendations, evaluation of team performance and that could potentially allow comparison between services.
METHODS

Participants
Health professionals who regularly participate in lung cancer MDT meetings at hospitals around Australia were invited to participate in the study, identified through the Lung Foundation Australia Lung Cancer Multidisciplinary Teams Directory, 24 professional networks and personal contacts. Invitations were issued directly to participants by email or via weblink distributed by lead MDT clinicians. Invitees for Round 3, the consensus conference, were identified from lead MDT clinicians who responded to the surveys.
Study design
We used a three-step modified Delphi process with two survey rounds and a consensus conference (Fig. 1) . The surveys were conducted electronically and the consensus conference was conducted by teleconference. The St Vincent's Human Research Ethics Committee approved the study, Reference No. LNR/15/ SVH/396. Written consent was waived as participation in the study implied consent.
Modified Delphi process
The Delphi process is a widely accepted method for gaining expert consensus and is becoming more commonly applied to clinical lung cancer care. [25] [26] [27] [28] Based upon methodology developed by the RAND Corporation 29 in the 1950s, initially for military purposes, modified Delphi processes are widely used in clinical research to gain expert opinion. Important components of the process include distribution of surveys, selection of survey participants, several iterations and predefinition of consensus. The Delphi process has been applied to a range of clinical lung cancer questions including risk factors for lung cancer, 30 patient-centred outcomes, 12 quality indicators for surgery in NSCLC 28 and synoptic operative reporting. 26 Likert-type scales, with scores based on measures of central tendency, are frequently employed in Delphi studies to evaluate levels of consensus. 31 
Data set development
Data elements in the surveys were based on (i) items collected by the St Vincent's Hospital Lung Cancer Multidisciplinary Team; (ii) a MeSH term search for 'Neoplasm lung', 'interdisciplinary care' and 'patient care team'; and (iii) review of the Cancer Australia Lung cancer (clinical) National best practice data set (NBPDS). 32 Data elements were categorized into eight domains: demographics, risk factors, biopsy data, staging, timeliness, treatment, follow-up and patient selection.
Round 1: survey
Round 1 (Appendix S2, Supplementary Information) asked participants for demographic information and then to rate data items on a five-point Likert scale (strongly agree to strongly disagree) as to whether they should be collected by MDT. Participants received the survey via weblink (Part 1) or by email (Part 2) after addresses were provided by lead clinicians with the consent of their MDT. Two reminders were sent to those in Part 2. Consensus was pre-specified as 80% agreement.
Round 2: survey
Participants for Round 2 (Appendix S3, Supplementary Information) reviewed data items that received less than 80% agreement in Round 1 and received two reminders. They were asked to reply 'yes', 'neutral' or 'no' for inclusion of data items. Consensus for those questions answerable by scale was pre-specified as 80% agreement. For Round 3, data items that achieved 80% consensus in Round 2 were added to those that had achieved 80% consensus in Round 1.
Round 3: consensus conference
Participants for the telephone-based consensus conference were invited from lead clinicians who responded to the surveys. One investigator acted as moderator (T.S.) and one investigator as observer (E.S.). The data set was discussed aiming to select data items that MDT should collect to (i) support treatment recommendations; (ii) support evaluation of team performance; and (iii) eventually benchmark services. Several key participants provided further feedback by telephone discussion after the consensus conference on feasibility and operational aspects.
Data analysis
Responses to Round 1 were evaluated for each variable on a 5-point Likert scale, with free text comments if required. Consensus for each variable was defined as 80% agreement. Data elements that failed to reach this level were circulated in the second round survey.
Responses to Round 2 were evaluated with a 3-point scale (yes/no/neutral) with consensus defined as 80% or above. The final data set was forwarded to Round 3, the consensus conference for discussion and development of a final workable data set.
RESULTS
Participants
The Round 1 survey was sent to 356 health professionals based on nine MDT via direct email: five in Victoria, three in NSW and one in South Australia. The survey was in addition sent as a weblink to lead clinicians from 10 MDT: 4 in Western Australia, 3 in NSW, 2 in Queensland and 1 in South Australia. There was a higher response to email invitations. Round 1 had 122 respondents, 83 of 356 (23%) from direct email and 39 (unknown denominator) from weblink invitations. Most respondents came from pulmonary medicine (32%), radiation oncology (18%) and medical oncology (16%). Invitations for Round 2 were issued directly via email to 98 participants: 83 from the email group and 15 from the weblink group who provided email addresses for further surveys. Round 2 had 52of 98 (53%) respondents with most from pulmonary medicine (31%), radiation oncology (15%) and nursing (13%). Invitations for Round 3 were issued by email to 33 lead MDT clinicians who had received invitations to participate in Rounds 1 and 2. There were 14of 33 (42%) participants who represented several fields: pulmonary medicine (7of 14, 50%), medical oncology (3 of 14, 21.4%), surgery (2 of 14, 14.3%), radiation oncology (1 of 14, 7.1%) and nursing (1 of 14, 7.1%) ( Table 1) .
Data items
The MeSH term literature search resulted in 41 citations (Appendix S1, Supplementary Information). Review of these papers resulted in five additional data items: (i) number of chronic illnesses; (ii) 90-day postoperative follow-up; (iii) cognitive function at baseline; (iv) geriatric measure of performance status; and Table 2) . These data elements, as well as the question of case selection, were presented in Round 3 (Table 3) . Round 3 led to the identification of 23 elements across the 8 domains. For treatment recommendation, 13 elements were identified (Table 4) . For team evaluation, 21 elements were identified (Table 5 ) with 11 elements common to both sets.
Subsequent feedback on feasibility and operational features was obtained from two lead clinicians who participated in Round 3. This feedback took place outside of the Delphi process and did not change consensus on which data elements should be collected. Two questions that were not fully resolved by the Delphi process were discussed, a working definition of COPD for the data set and the optimal co-morbidity index that should be collected by the MDT.
DISCUSSION
Most MDT clinicians have little guidance on the best approach to data collection for MDT meetings. In this study, recognized methodology was employed to obtain consensus for appropriate data elements for the MDT. A relatively large number of health professionals participated to identify key data elements resulting in a data set comprising 23 elements across 8 domains relevant to treatment recommendation, evaluation of team performance and with potential for future benchmarking. Explicitly, to our knowledge this is the first consensus-based data set in development specifically for use at MDT meetings. This fills a gap in the current literature, as although existing data sets have overlapping objectives, we perceive a need for a modest, practical and specific MDT data set.
This study has a number of limitations. Response rates appear relatively low, however it is worth noting that 23% of the participants invited (n = 356) to Round 1 directly through email completed the first survey, which is considered large for Delphi studies in lung cancer. 33 A second cohort invited indirectly to Round 1 via a weblink generated an additional 39 responses, however the denominator for this group is not known. Recent Delphi studies looking at aspects of lung cancer care have had invited participant groups ranging from 6 to 139 individuals and response rates ranging from 19.5 to 100%. 33 The size of the invited participant group in our study could be considered ambitious, however we wished to contact as many members of Australian lung cancer MDTs as possible; our response rates appear reasonable compared with other studies. We also acknowledge that these findings result from a consensus process and therefore do not represent gold standard guidelines. However, this is a first attempt to develop a data set for lung cancer MDT and we anticipate further refinement of the data set in future studies. Important voices are missing, including patient participants, psychology and liaison psychiatry. Some specialty groups are under-represented including radiology, pathology and palliative care. We acknowledge the importance of patient participants, however as an initial development process our focus was on obtaining consensus from health professionals who actively participate in MDT meetings; future work will involve patient participants to optimize the data set. There may be a relative absence of psychologists and possibly psychiatrists who attend MDT meetings and this deserves further investigation particularly given the high rates of psychological co-morbidity associated with lung cancer. 34 There are several possible reasons for the lower rates of participation from radiology, pathology and palliative care. There may be fewer representatives of these disciplines in each MDT. Clinicians more closely involved in active treatment (respiratory medicine, oncology, surgery) may have a greater interest in developing a clinical data set. The identification of participants for Round 3 may have been too limited as fewer radiologists, pathologists and palliative care physicians act as MDT lead clinicians. Not every state or territory in Australia was represented in the consensus process; however, we did go to considerable lengths to identify a broad cross-section of clinicians from specialist disciplines. Particular data elements of interest, such as the timing of GP referral for specialist care, were considered in the surveys but did not receive adequate support (80% consensus) for submission to the consensus conference (Round 3). There are unresolved data items in our dataset: COPD, co-morbidity index and case selection. For COPD, both ICHOM and the NLCA record forced expiratory volume in 1 s (FEV 1 ), our discussions also considered the value of gas exchange capacity. Co-morbidity indices such as the Charlson co-morbidity index 35 or the Colinet simplified co-morbidity score 36 may be too complex for MDT to collect. Important risk factors, such as idiopathic pulmonary fibrosis (IPF), were not included in the data set; this can be explained, for this first attempt, by the absence of IPF in the data sources upon which this study was based. These data sets included not only our own institutional database but also the Cancer Australia Lung cancer (clinical) NBPDS. 32 The selection of patients for presentation remains unresolved: recommendations vary from cancer statutory bodies and actual selection may reflect caseload. Certain data elements are missing, in particular patient-reported outcomes and newer treatment elements such as immunotherapy. These will be addressed in future work as we regard this data set as a starting point for MDT. The collection of case-mix variables was not a specific aim and a key variable, socioeconomic status (SES), is not included. We recognize the importance of case-mix adjustment and acknowledge the lack of this data element in particular. However, case-mix adjustment generally occurs in subsequent analyses of data whereas our primary aim was to develop a data set for real-time use. To address this, we have included several case-mix variables such as performance status (ECOG) and smoking status. Measures of COPD such as FEV 1 can easily be incorporated. There are also a number of tools that can link to SES via postcode through the Australian Bureau of Statistics 37 for case-mix analyses. We anticipate that these analyses would not routinely be performed by the individual MDT but acknowledge their importance, particularly for the purposes of auditing current practice. We do not provide a data dictionary but would define our data elements according to published definitions from statutory bodies.
This study highlights a number of future research questions and studies in addition to seeking patient representatives for key outcome measures. The collection of case-mix variables and testing of case-mix adjustment needs to be undertaken in further benchmarking. Data definitions will be determined as above from published definitions. Key quality indicators for professional clinical care, organization of care and patient outcomes 38 will need to be tested for benchmarking. Integration and harmonization of this data set between centres will require further work. There may be variations in care and in data quality between centres. Appropriate audit and feedback strategies within and between centres will require testing and verification. In the first instance, the data set will be implemented for the St Vincent's Hospital (Sydney) Lung Cancer MDT with subsequent testing of feasibility and acceptance with other MDT.
We have defined a consensus recommendation for data elements to be collected routinely at lung cancer MDT meetings in order to optimize treatment recommendations, evaluate MDT performance and potentially facilitate benchmarking between centres. The data set has been deliberately kept to a modest size for feasibility of implementation, can be modified to fit local requirements and may represent a starting point for new MDT and new data collection. 
